Zhonglin Hao (IMAGE)

University of Kentucky

Zhonglin Hao

Caption

Markey medical oncologist Zhonglin Hao is leading a clinical trial for ZG006, a more powerful successor to FDA-approved immunotherapy that could help small cell lung cancer patients who’ve run out of options. 

Credit

Photo by Shaun Ring

Usage Restrictions

Available for editorial use with credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.